Current laboratory practices in the diagnosis and management of haemophilia: A global assessment

Haemophilia

Volumn 21, Issue 4, 2015, Pages 550-557

  Kitchen, S ^a   Signer Romero, K ^b   Key, N S ^c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b PSL RESEARCH UNIVERSITY   (France)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Assay standardisation; Coagulation assays; Factor VIII assays; Guidelines; Haemophilia A; Haemophilia B

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; REAGENT; CHROMOGENIC SUBSTRATE;

ARTICLE; ASSAY; BLOOD CLOTTING TEST; CALIBRATION; FACTOR IX ASSAY; FACTOR VIII ASSAY; GEOGRAPHIC DISTRIBUTION; GOOD LABORATORY PRACTICE; HEALTH CARE MANAGEMENT; HEALTH PERSONNEL ATTITUDE; HEMATOLOGY TEST KIT; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LABORATORY; LABORATORY DIAGNOSIS; LABORATORY PERSONNEL; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; CHEMISTRY; METABOLISM; PATHOLOGY; QUESTIONNAIRE; STANDARDS;

BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; LABORATORIES; PARTIAL THROMBOPLASTIN TIME; SURVEYS AND QUESTIONNAIRES;

EID: 84931956842     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12639     Document Type: Article

References (21)

1. Skinner MW. Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. Br J Haematol 2011; 154: 704-14. doi: 10.1111/j.1365-2141.2011.08765.x.
2. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
3. Calculated by comparing HA-HB ratio to reported HA prevalence; HA-HB ratio obtained from World Federation of Hemophilia. Report on the annual global survey 2008. Montreal, QC: World Federation of Hemophilia, 2009.
4. Stonebraker JS, Bolton-Maggs PH, Michael SJ, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 2012; 18: e91-4.
5. Skinner MW. WFH-the cornerstone of global development: 45 years of progress. Haemophilia 2008; 14(Suppl. 3): 1-9.
6. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
7. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
8. Jennings I, Kitchen DP, Woods TA, Kitchen S, Walker ID, Preston FE. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia 2009; 15: 571-7.
9. Bolton-Maggs PH. Optimal haemophilia care versus the reality. Br J Haematol 2006; 132: 671-82.
10. Rodeghiero F, Ruiz-Saez A, Bolton-Maggs PH, Hayward CP, Nair SC, Srivastava A. Laboratory issues in bleeding disorders. Haemophilia 2008; 14(Suppl. 3): 93-103.
11. Preston FE, Kitchen S, Jennings I, Woods TA, Makris M. SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria? J Thromb Haemost 2004; 2: 271-4.
12. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
13. Fritsma GA, Dembitzer FR, Randhawa A et al. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. Am J Clin Pathol 2012; 137: 904-8.
14. The National Committee for Clinical Laboratory Standards (NCCLS). Determination of factor coagulant activities; approved guideline. NCCLS document H48-A. NCCLS 1997; 17.
15. Kitchen S, McCraw A, Echenagucia M. Diagnosis of Hemophilia and Other Bleeding Disorders. A Laboratory Manual, 2nd edn. Montreal, QC: World Federation of Hemophilia, 2010.
16. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
17. Mackie I, Cooper P, Lawrie A et al. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 2013; 35: 1-13.
18. Ingerslev J, Jankowski MA, Weston SB, Charles LA, ReFacto Field Study P. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2: 623-8.
19. Walker ID. UK NEQAS for blood coagulation. Report on Survey 170. Available at http://www.ukneqasbc.org/content/PageServer.asp?S=1030685499&C=1252&CID=1, 2008. Accessed August 1, 2014.
20. Gomez K, Chitlur M, Panel G. Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A. Thromb Haemost 2013; 109: 738-43.
21. Lattes S, Appert-Flory A, Fischer F, Jambou D, Toulon P. Measurement of factor VIII activity using one-stage clotting assay: a calibration curve has not to be systematically included in each run. Haemophilia 2011; 17: 139-42.